Healthcare >> CEO Interviews >> January 13, 2000

Leonard Bell – Alexion Pharmaceuticals Inc (alxn)

LEONARD BELL, M.D. is the principal founder of Alexion, and, since 1992, the President, Chief Executive Officer, and a Director of the Company. Alexion became a publicly traded company on the NASDAQ National Market in 1996. From 1990 to 1993, Dr. Bell was an Assistant Professor in the Department of Internal Medicine (Cardiology) at the Yale University School of Medicine as well as an Attending Physician at the Yale-New Haven Hospital and, from 1991-1993, an Assistant Professor in the Department of Pathology and co-Director of the Program in Vascular Biology at Yale Medical School. Dr. Bell was the recipient of the Physician Scientist Award from the National Institutes of Health. From 1986 through 1990, Dr. Bell did various postdoctoral research and clinical training in Cardiology and Pathology at the Yale Medical School. Dr. Bell is the recipient of various honors and awards from academic and professional organizations and his work has resulted in more than 45 scientific publications, invited presentations and patent applications. Dr. Bell is a Director of CURE and an invited Member of the State of Connecticut Governor's Council on Economic Competitiveness and Technology. Dr. Bell received his A.B. from Brown University and M.D. from Yale University. Dr. Bell received his clinical training from Yale University in internal medicine and cardiology and is currently an Adjunct Assistant Professor of Medicine and Pathology at Yale. Profile
TWST: Give us a brief overview of Alexion Pharmaceuticals, Inc.

Dr. Bell: I was the principal founder of Alexion in 1992. We have

focused on developing novel anti-inflammatory drugs. We